This section of the website is for UK Healthcare Professionals only.
If you are a patient please click here. If you are a member of the public please click here.

This section of the website is for
UK Healthcare Professionals only.
If you are a patient please click here.
If you are a member of the public please click here.

A generally manageable safety profile

Discover how Bristol-Myers Squibb is committed
to supporting you when managing immune-related
adverse events

Discover more

OPDIVO stimulates the immune system to fight cancer cells1

Discover more

Which patients could benefit from OPDIVO?1

  • OPDIVO as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
  • OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
    after prior chemotherapy in adults.
  • OPDIVO as monotherapy is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) after prior
    therapy in adults.

1506UK1600143-01
Date of preparation: April 2016

1506UK1600143-01
Date of preparation: April 2016

References

  1. OPDIVO Summary of Product Characteristics.
  2. Robert C et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372(4):320-30.
  3. Brahmer J et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med 2015;373(2):123-35.
  4. Borghaei H, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med 2015;373(17):1627-39.
  5. Motzer RJ et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015;373(19):1803-1813.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

The information on this website is intended for Healthcare Professionals (HCPs) only

Please confirm you are a UK Healthcare Professional

1506UK1600143-01
Date of preparation: April 2016

The information on this website is intended for Healthcare Professionals (HCPs) only

Please confirm you are a UK Healthcare Professional